According to our latest study on "mHealth Market Forecast to 2028 – COVID-19 Impact and Analysis – by Service, Devices, and End User" the market is projected to reach US$ 410.39 billion by 2028 from US$ 70.83 billion in 2021; it is estimated to grow at a CAGR of 28.5% from 2021 to 2028. The report highlights the key factors and trends impacting the market and focuses on prominent players and their game-changing strategies. The increasing adoption of smartphones and other mobile platforms, and rapid spread of COVID-19 are driving the mHealth market progress. However, security and privacy issues hinder the market growth.

Mobile health (mHealth) is a technique that includes the use of mobile commination devices, such as mobile phones, tablets, PDAs (personal digital assistants) and other wireless devices for distributing health services and information. mHealth unlocks the new opportunities for improving monitoring of chronic conditions and help with developing the prevention aspect of the healthcare system. mHealth enables to offer the services on consultation, care management, diagnosis, and self-management services by using information & communication technologies (ICT). It involves a wide variety of technologies and tactics to deliver virtual medical, health, and education services to the users. mHealth is a collection of means that is used to enhance care and education delivery. mHealth include instruments, apparatus, machines or software (including mobile applications) that are involved in the delivery of healthcare services.

Diabetes is a chronic, metabolic disorder that refers to the condition created by the body's inability to regulate glucose levels. The medical profession has postulated that patients could benefit from a system providing continuous glucose readings. The number of people with diabetes is increasing across the world, and ~90% of patients diagnosed with the condition have Type 2 diabetes mellitus; about one-fifth of people with Type 2 diabetes are on insulin treatment. The global burden of Type 2 diabetes has prompted efforts to develop mobile technologies for self-monitoring of blood glucose. More than 30 million Americans have some form of diabetes mellitus, which includes Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Patients with diabetes have prolonged periods of high blood glucose, which results from insufficient levels of insulin or an inadequate cellular response to insulin. In the US, Type 2 (insulin-resistant) diabetes accounts for ~90–95% of all patients with diabetes, while Type 1 (insulin-insufficient) diabetes accounts for 5%. Management of diabetes varies depending on the type and severity. For Type 1 diabetes patients, insulin is a life-long treatment, with a wide spectrum of doses including multiple dose injections of insulin pumps (also known as continuous subcutaneous insulin infusion). A wide variety of home glucometers are available that are portable, inexpensive, reliable, and sensitive, and these machines use smaller volumes of blood than their conventional counterparts. Wearable insulin pumps and continuous glucose monitoring systems (CGMS) have given more freedom to many individuals with diabetes, along with providing scope for better treatments with real-time monitoring. Insulin deficiency can have serious side effects. By wearing CGMs and insulin pumps, patients are less likely to experience insulin deficiency. Moreover, when connected to a smartphone app, a CGMS or insulin pump gives continuous glucose updates. CGMS collect data so patients can identify trends and triggers.